Cover Image

Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series

BackgroundAnti-CD20 therapies are widely used in patients with multiple sclerosis (pwMS). Recognition of rare adverse reactions to these therapies is therefore important.ObjectivesTo report dermatological and gastrointestinal adverse reactions in a single-center cohort of ocrelizumab treated pwMS.Me...

Full description

Saved in:
Bibliographic Details
Main Authors: Höpner, Lena Katharina (Author) , Marschall, Ella (Author) , Schindler, Patrick (Author) , Frauendorf, Vilmar (Author) , Böhmig, Michael (Author) , Rakers, Florian (Author) , Karimi, Diana (Author) , Faber, Claudius (Author) , Ruprecht, Klemens (Author) , Otto, Carolin (Author)
Format: Article (Journal)
Language:English
Published: 09 March 2026
In: Frontiers in immunology
Year: 2026, Volume: 17, Pages: 1-11
ISSN:1664-3224
DOI:10.3389/fimmu.2026.1753387
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2026.1753387
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1753387/full
Get full text
Author Notes:Lena K. Höpner, Ella Marschall, Patrick Schindler, Vilmar Frauendorf, Michael Böhmig, Florian Rakers, Diana Karimi, Claudius Faber, Klemens Ruprecht and Carolin Otto
Description
Summary:BackgroundAnti-CD20 therapies are widely used in patients with multiple sclerosis (pwMS). Recognition of rare adverse reactions to these therapies is therefore important.ObjectivesTo report dermatological and gastrointestinal adverse reactions in a single-center cohort of ocrelizumab treated pwMS.MethodsRetrospective analysis conducted at a multiple sclerosis outpatient clinic of Charité - Universitätsmedizin Berlin, Berlin, Germany, between March 2020 and February 2025.ResultsAmong 447 ocrelizumab treated pwMS, 8 (1.8%) developed dermatological adverse reactions after a median (range) of 20.5 (6-72) months following start of therapy, including lichen planus (n=2), rosacea (n=1), psoriatic arthritis (n=1), guttate psoriasis (n=1), psoriasis vulgaris (n=1), nail psoriasis (n=1) and palmoplantar psoriasis (n=1). Another 5 (1.1%) patients developed gastrointestinal adverse reactions 24 (0.25-77) months after starting therapy, including Crohn’s disease (n=1), toxic colitis (n=1), lymphocytic colitis (n=1), perforated appendicitis (n=1) and acute cholecystitis (n=1). Due to these adverse reactions, ocrelizumab was stopped in 7/13 patients. At last follow-up, adverse reactions had completely improved in 4/13, incompletely improved in 6/13, and persisted in 3/13 patients.ConclusionsClinicians should be aware of dermatological and gastrointestinal adverse reactions associated with ocrelizumab, which can develop from a few weeks up to six years after start of therapy.
Item Description:Veröffentlicht: 09. März 2026
Gesehen am 15.05.2026
Physical Description:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2026.1753387

Similar Items